

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
THERAPEUTIC STUDIES ONLY (TXCA=Y)  
64% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	1558	560	36%	881	-676	987	-571
ERLYTX	76	314	413%	494	418	444	368
GI	476	77	16%	121	-354	175	-301
GU	450	199	44%	313	-136	316	-134
GYN	57	0	0%	0	-57	0	-57
LEUK	150	76	51%	119	-30	85	-65
LUNG	524	167	32%	262	-261	284	-240
LYMPH	172	15	9%	23	-148	18	-154
MELAN	55	60	109%	94	39	152	97
MMYEL	147	56	38%	88	-58	84	-63
OTHER	0	38		59	59	51	51
SXQOL	0	6		9	9	6	6
<b>Total</b>	<b>3665</b>	<b>1568</b>		<b>2463</b>	<b>-1195</b>	<b>2602</b>	<b>-1063</b>

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
NON-THERAPEUTIC STUDIES ONLY (TXCA=N)  
64% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
	0	6		9	9	6	6
BREAST	37	201	543%	316	279	223	186
CCD	0	957		1505	1505	1506	1506
GU	0	0		0	0	0	0
LEUK	69	11	16%	17	-51	11	-58
LUNG	43	448	1042%	704	661	635	592
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	0		0	0	0	0
PREV	0	32		50	50	84	84
SURV	0	62		97	97	96	96
<u>SXQOL</u>	<u>878</u>	<u>3</u>	<u>0%</u>	<u>4</u>	<u>-873</u>	<u>3</u>	<u>-875</u>
Total	1172	1720		2702	1532	2564	1392

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE**  
**ALL ACCRUAL REGISTRATIONS**  
**64% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
	0	6		9	9	6	6
BREAST	1595	761	48%	1197	-397	1210	-385
CCD	0	957		1505	1505	1506	1506
ERLYTX	76	314	413%	494	418	444	368
GI	476	77	16%	121	-354	175	-301
GU	450	199	44%	313	-136	316	-134
GYN	57	0	0%	0	-57	0	-57
LEUK	219	87	40%	136	-82	96	-123
LUNG	567	615	108%	967	400	919	352
LYMPH	225	15	7%	23	-201	18	-207
MELAN	55	60	109%	94	39	152	97
MMYEL	239	56	23%	88	-150	84	-155
OTHER	0	38		59	59	51	51
PREV	0	32		50	50	84	84
SURV	0	62		97	97	96	96
SXQOL	878	9	1%	14	-863	9	-869
<b>Total</b>	<b>4837</b>	<b>3288</b>		<b>5167</b>	<b>337</b>	<b>5166</b>	<b>329</b>

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)  
64% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	1012	360	36%	566	-445	587	-425
ERLYTX	76	203	267%	319	243	286	210
GI	418	53	13%	83	-334	112	-306
GU	375	129	34%	202	-172	209	-166
GYN	57	0	0%	0	-57	0	-57
LEUK	122	48	39%	75	-46	55	-67
LUNG	441	129	29%	202	-238	207	-234
LYMPH	129	14	11%	22	-106	17	-112
MELAN	55	41	75%	64	9	95	40
MMYEL	85	55	65%	86	1	83	-2
OTHER	0	38		59	59	51	51
SXQOL	0	6		9	9	6	6
<b>Total</b>	<b>2770</b>	<b>1076</b>		<b>1687</b>	<b>-1077</b>	<b>1708</b>	<b>-1062</b>

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)  
64% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
	0	6		9	9	6	6
BREAST	10	200	2000%	314	304	222	212
CCD	0	705		1109	1109	1076	1076
GU	0	0		0	0	0	0
LEUK	69	11	16%	17	-51	11	-58
LUNG	30	303	1010%	476	446	443	413
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	0		0	0	0	0
PREV	0	18		28	28	64	64
SURV	0	45		70	70	66	66
SXQOL	740	3	0%	4	-735	3	-737
Total	994	1291		2027	1035	1891	897

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY  
64% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
	0	6		9	9	6	6
BREAST	1022	560	55%	881	-140	809	-213
CCD	0	705		1109	1109	1076	1076
ERLYTX	76	203	267%	319	243	286	210
GI	418	53	13%	83	-334	112	-306
GU	375	129	34%	202	-172	209	-166
GYN	57	0	0%	0	-57	0	-57
LEUK	191	59	31%	92	-98	66	-125
LUNG	471	432	92%	679	208	650	179
LYMPH	182	14	8%	22	-159	17	-165
MELAN	55	41	75%	64	9	95	40
MMYEL	177	55	31%	86	-90	83	-94
OTHER	0	38		59	59	51	51
PREV	0	18		28	28	64	64
SURV	0	45		70	70	66	66
SXQOL	740	9	1%	14	-725	9	-731
<b>Total</b>	<b>3764</b>	<b>2367</b>		<b>3717</b>	<b>-40</b>	<b>3599</b>	<b>-165</b>

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE  
ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES  
64% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase &lt;Decrease&gt; from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase &lt;Decrease&gt; from Base</u>
BREAST	65	488	751%	767	702	831	766
CCD	0	957		1505	1505	1506	1506
GI	81	27	33%	42	-38	36	-45
GU	215	120	56%	188	-26	172	-43
LEUK	0	11		17	17	11	11
LUNG	53	25	47%	39	-13	62	9
LYMPH	7	0	0%	0	-7	0	-7
MELAN	0	3		4	4	63	63
MMYEL	0	52		81	81	80	80
OTHER	0	1		1	1	6	6
PREV	0	32		50	50	84	84
SURV	0	62		97	97	96	96
<u>SXQOL</u>	<u>878</u>	<u>9</u>	<u>1%</u>	<u>14</u>	<u>-863</u>	<u>9</u>	<u>-869</u>
Total	1299	1787		2805	1510	2956	1657

## SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		A221505	ALLIANCE			2			
		EA8153	ECOG-ACR			2			
		EAQ162CD	ECOG-ACR			2			
BREAST	II	NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	NRG	13APR2017:00:00:00		1		0.2	
		S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	SWOG	07JUL2016:00:00:00	25	247	333	4.7	Feb-2020
	II-III	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG	24DEC2014:00:00:00		1		0.0	
	III	A011106 Breast, Neoadj, ALTERNATE study	ALLIANCE	15FEB2014:00:00:00		74		3.5	
		A011401 Breast, adj, Stage II/III HER2-, weight loss	ALLIANCE	29AUG2016:00:00:00		170		9.8	
		A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	ALLIANCE	08DEC2016:00:00:00		50		3.8	
		B51 Breast, Regional Nodal XRT	NRG	22AUG2013:00:00:00		29		0.7	
		B55 Brst, Adj Olaparib for BRCA,TNBC	NRG	03JUL2014:00:00:00		30		1.2	
		E2112 Brst,Adv,Exemestane+/-Entinostat	ECOG-ACRIN	02JAN2014:00:00:00		53		1.2	
		EA1151 Brst, Tomosynthesis Mammographic Screening	ECOG-ACRIN	06JUL2017:00:00:00		164		26.0	
		NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG	22JAN2015:00:00:00		59		1.8	
		S1207 Brst,Adj,Endocrine+/-Everolimus	SWOG	03SEP2013:00:00:00	59	1675	1900	27.7	Apr-2019
		S1222 Brst,Fulv. +/- Ever. +/- Anastr.	SWOG	09MAY2014:00:00:00		37	840		Feb-2015 Temp Close
		S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	SWOG	15NOV2016:00:00:00	21	245	1000	19.0	Nov-2021
	OTHER	A221405 Breast, ET interruption, Pregnancy Outcomes	ALLIANCE	15OCT2015:00:00:00		12		0.7	
		E1Z11 Brst,Genetic Predictors of AIMSS	ECOG-ACRIN	10MAY2013:00:00:00		153		0.7	
CCD	III	A011104 Preoperative Breast MRI	ALLIANCE	21FEB2014:00:00:00		14		0.2	
		A191402C PROS, Testing Decision Aids for Minority Men	ALLIANCE	14JUL2017:00:00:00		11		1.2	
		S1415CD TrACER CSF Standing Order Intervention for FN	SWOG	01SEP2016:00:00:00	23	2043	3960	104.8	Feb-2020
		S1703 Met Breast, STM-monitoring v Usual Care	SWOG	16JUL2018:00:00:00		1	0	1056	
	OTHER	S1417CD Colorectal, Cost Cohort Study	SWOG	13MAY2016:00:00:00	27	292	374	18.8	Dec-2018
ERLYTX	II	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	ALLIANCE	06AUG2015:00:00:00		5		0.0	
		S1609 Rare Tumor, Comb Nivo/Ipi	SWOG	13JAN2017:00:00:00	19	523	707	31.7	Jan-2019
	II-III	A071102 GBM, adj TMZ +/- Veliparib	ALLIANCE	19SEP2014:00:00:00		49		1.7	
		ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	COG	16MAY2014:00:00:00		9		0.3	
	OTHER	EAY131 MATCH	ECOG-ACRIN	12AUG2015:00:00:00		118		1.8	
GI	II	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	ALLIANCE	01DEC2016:00:00:00		15		0.5	
		EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	ECOG-ACRIN	06NOV2015:00:00:00		4		0.0	
		NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG	12OCT2016:00:00:00		6		0.0	
		S1613 mCRC, Adv/Met, TP vs CETIRI	SWOG	09OCT2017:00:00:00	10	8	130	1.3	Mar-2026
	II-III	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	ALLIANCE	13JAN2012:00:00:00		156		2.3	
	III	A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC	ALLIANCE	12SEP2017:00:00:00		5		0.8	



## SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG	07NOV2017:00:00:00		2		0.3	
GU	II	S1500 pRCC,Adv, Sunitinib vs MET inhib	SWOG	05APR2016:00:00:00	28	104	180	5.5	Sep-2019
		S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	SWOG	07FEB2017:00:00:00	18	66	148	5.2	Nov-2019
	II-III	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG	30DEC2016:00:00:00		1		0.0	
	III	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	ALLIANCE	01JUL2015:00:00:00		3		0.2	
		A031501 Bladder, MIBC/Loc Adv, Adjuv Pembro vs Obs	ALLIANCE	21SEP2017:00:00:00		7		1.2	
		EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	ECOG-ACRIN	02FEB2017:00:00:00		15		1.5	
		R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	NRG	07JUL2011:00:00:00		87		3.5	
		S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	SWOG	07FEB2017:00:00:00	18	135	969	10.5	Mar-2025
LEUK	I	S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP	SWOG	01APR2014:00:00:00	52	41	38	0.7	Apr-2018
	I-II	S1318 ALL, Age 65+, Ph±, Blinatumomab	SWOG	12JAN2015:00:00:00		47	44		Sep-2017 Temp Close
	II	S1712 CML, chronic phase, TKI +/- Ruxolitinib	SWOG	20JUL2018:00:00:00	1	0	84		
	II-III	S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics	SWOG	22DEC2017:00:00:00	7	52	1670	8.3	> 15 Yrs
	III	E1910 BCR-ABL-neg, B ALL, Blinatumomab	ECOG-ACRIN	23DEC2013:00:00:00		91		2.2	
		E2906 AML, Age 60+, Clo vs Dauno+Cy	ECOG-ACRIN	24FEB2011:00:00:00		75		0.0	
	OTHER	NHLBIMDS LEUK, National MDS Study	ECOG-ACRIN	05APR2016:00:00:00		16		1.5	
LUNG	II	EA5161 Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo	ECOG-ACRIN	02MAY2018:00:00:00		2		0.6	
		S1400F Non-Match: MEDI4736 + Tremelimumab	SWOG	02OCT2017:00:00:00	10	28	132	2.8	Aug-2021
		S1400K c-Met: ABBV-399 (Process II)	SWOG	05FEB2018:00:00:00	6	26	44	4.3	Dec-2018
		S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac	SWOG	09AUG2018:00:00:00	0	0	66		
	II-III	NRGCC003 SCLC, PCI or HA-PCI	NRG	07DEC2015:00:00:00		4		0.0	
	III	A081105 ALCHEMIST1, EGFR mut, Erlotinib	ALLIANCE	02JAN2014:00:00:00		40		1.2	
		C30610 SCLC, Thoracic RT	ALLIANCE	21MAR2008:00:00:00		56		0.2	
		E4512 ALCHEMIST2, ALK mut, Crizotinib	ECOG-ACRIN	18AUG2014:00:00:00		9		0.3	
		EA5142 ALCHEMIST3, Non-match, Nivolumab	ECOG-ACRIN	16MAY2016:00:00:00		64		4.7	
	OTHER	A151216 ALCHEMIST0 - screening	ALLIANCE	06FEB2014:00:00:00		578		22.3	
		S1400 SCCA,Adv, Biomarker Master	SWOG	15JUN2014:00:00:00	50	1755		39.0	
	PILOT	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	SWOG	03NOV2017:00:00:00	9	4	28	0.7	Aug-2021
LYMPH	II	S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	SWOG	10AUG2017:00:00:00	12	6	150	0.7	> 15 Yrs
	III	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	ALLIANCE	15JUL2016:00:00:00		6		0.0	
		EA4151 Lymph, AHCT +/-Ritux, MRD Neg	ECOG-ACRIN	29AUG2017:00:00:00		8		1.3	
MELAN	II	S1320 Adv, BRAF mut, Inter v Contin	SWOG	22JUL2014:00:00:00	48	220	280	3.7	Dec-2019
		S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	SWOG	20OCT2016:00:00:00	22	13	77	1.2	Feb-2023
		S1607 MELAN, Adv, T-VEC, MK-3475	SWOG	02OCT2017:00:00:00	10	2	64	0.3	> 15 Yrs
		S1616 MELAN, Adv, Ipilimumab ± Nivolumab	SWOG	17JUL2017:00:00:00	13	22	94	2.5	Dec-2020

## SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
	II-III	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	ECOG-ACRIN	01MAR2016:00:00:00		36		0.0	
	III	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	ECOG-ACRIN	15DEC2015:00:00:00		27		0.5	
MMYEL	II	S1702 AL Amyloidosis, Relapsed, Isatuximab	SWOG	08MAR2018:00:00:00	5	4	39	0.7	Jul-2022
	III	E1A11 MM, frontline, BLD vs CLD	ECOG-ACRIN	22NOV2013:00:00:00		210		5.5	
OTHER	I-II	A091304 Adv Sarc, MLN0128 v Pazopanib, Phi/II	ALLIANCE	26JAN2015:00:00:00		27		2.7	
	II	A091305 HN, Adv, Thyroid PPAR agonist + Chemo	ALLIANCE	01SEP2014:00:00:00		2		0.0	
		A091401 Sarc,	ALLIANCE	18JUN2015:00:00:00		10		0.7	
		A091404 HN, AR+, Enzalutamide	ALLIANCE	25SEP2015:00:00:00		9		0.2	
		EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	ECOG-ACRIN	29MAR2016:00:00:00		9		0.8	
		EAF151 Brain, GBM, Bev, Blood Volume	ECOG-ACRIN	14APR2017:00:00:00		2		0.3	
		NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG	28AUG2015:00:00:00		1		0.0	
	II-III	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG	06FEB2016:00:00:00		3		0.0	
		NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG	21APR2014:00:00:00		5		0.2	
		R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	NRG	18MAR2013:00:00:00		3		0.0	
	III	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	NRG	12APR2010:00:00:00		1		0.0	
		N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	ALLIANCE	22SEP2009:00:00:00		7		0.3	
		R0724 Cervical, Chem+RT +/- Adj. Chemo	NRG	15JAN2014:00:00:00		1		0.0	
	OTHER	EAQ152 Communication & education in tumor profiling	ECOG-ACRIN	26SEP2016:00:00:00		11		0.0	
PREV	III	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	ALLIANCE	01FEB2015:00:00:00		3		0.0	
		S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	SWOG	01MAR2013:00:00:00	65	208	480	3.7	Oct-2024
SURV	III	E1Q11 EROS: Reproductive Health in Cancer Survivors	ECOG-ACRIN	30SEP2015:00:00:00		12		0.5	
		S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	SWOG	15SEP2017:00:00:00	11	24	817	3.2	> 15 Yrs
	OTHER	EA9131 Leuk, Strategy to decrease early APL deaths	ECOG-ACRIN	16AUG2017:00:00:00		10		1.2	
		S1316 Compar. Effectiv. Trial for MBO	SWOG	01AUG2014:00:00:00	48	158	200	3.0	Sep-2019
SXQOL	III	A221101 Glioma, Nuvigil/Placebo Fatigue	ALLIANCE	03JUN2013:00:00:00		20		0.3	
		NRGGU003 Pros, Post-Prostatectomy HYPORIT vs COPORT	NRG	28JUL2017:00:00:00		6		0.8	

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

## OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
OTHER	BREAST	Y	ECOG-ACRIN	E1Z11 Brst,Genetic Predictors of AIMSS	E1Z11	Y	
		Y	ALLIANCE	A221405 Breast, ET interruption, Pregnancy Outcomes	A221405	Y	
	CCD	N		S1417CD Colorectal, Cost Cohort Study		Y	
ERLYTX	Y	ECOG-ACRIN	EAY131 MATCH		EAY131	N	
LEUK	Y	ECOG-ACRIN	NHLBIMDS LEUK, National MDS Study		NHLBI-MDS	Y	
LUNG	Y	SWOG	S1400 SCCA,Adv, Biomarker Master		S1400	N	
	Y	ALLIANCE	A151216 ALCHEMIST0 - screening		A151216	N	
OTHER	Y	ECOG-ACRIN	EAQ152 Communication & education in tumor profiling		EAQ152	Y	
SURV	Y	SWOG	S1316 Compar. Effectiv. Trial for MBO		S1316	Y	
	Y	ECOG-ACRIN	EA9131 Leuk, Strategy to decrease early APL deaths		EA9131	Y	
I	LEUK	N		S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP		N	
I-II	LEUK	Y	SWOG	S1318 ALL, Age 65+, Ph±, Blinatumomab	S1318	N	Y
	OTHER	Y	ALLIANCE	A091304 Adv Sarc, MLN0128 v Pazopanib, Ph/II	A091304	N	
II	BREAST	Y	SWOG	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	S1416	N	
	Y	NRG	NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv		NRG-BR005	N	
ERLYTX	Y	SWOG	S1609 Rare Tumor, Comb Nivo/lpi		S1609	N	
	Y	ALLIANCE	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib		A071401	N	
GI	Y	SWOG	S1613 mCRC, Adv/Met, TP vs CETIRI		S1613	N	
	Y	ECOG-ACRIN	EA2142 GI NEC, Adv G3, EP vs TMZ + CAP		EA2142	N	
	Y	NRG	NRGGI002 Rectal, Ph II, Sensitization using TNT		NRG-GI002	N	
	Y	ALLIANCE	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT		A021501	N	
GU	Y	SWOG	S1500 pRCC,Adv, Sunitinib vs MET inhib		S1500	N	
	Y	SWOG	S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab		S1605	N	
LEUK	Y	SWOG	S1712 CML, chronic phase, TKI +/- Ruxolitinib		S1712	N	
LUNG	Y	SWOG	S1400K c-Met: ABBV-399 (Process II)		S1400K	N	
	Y	SWOG	S1400F Non-Match: MEDI4736 + Tremelimumab		S1400F	N	
	Y	SWOG	S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac		S1701	N	
	Y	ECOG-ACRIN	EA5161 Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo		EA5161	N	
LYMPH	Y	SWOG	S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob		S1608	N	
MELAN	Y	SWOG	S1320 Adv, BRAF mut, Inter v Contin		S1320	N	
	Y	SWOG	S1607 MELAN, Adv, T-VEC, MK-3475		S1607	N	
	Y	SWOG	S1616 MELAN, Adv, Ipilimumab ± Nivolumab		S1616	N	
	Y	SWOG	S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)		S1512	N	
MMYEL	Y	SWOG	S1702 AL Amyloidosis, Relapsed, Isatuximab		S1702	N	
OTHER	Y	NRG	NRGBN001 HN, novel vs. std chemoradiation + chemo		NRG-BN001	N	
	Y	ALLIANCE	A091401 Sarc,		A091401	N	
	Y	ALLIANCE	A091305 HN, Adv, Thyroid PPAR agonist + Chemo		A091305	N	

## OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
		Y	ALLIANCE	A091404 HN, AR+, Enzalutamide	A091404	N	
		Y	ECOG-ACRIN	EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	EA3132	N	
		Y	ECOG-ACRIN	EAF151 Brain, GBM, Bev, Blood Volume	EAF151	N	
PILOT	LUNG	Y	SWOG	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	S1619	N	
II-III	BREAST	Y	NRG	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG-BR002	N	
	ERLYTX	Y	ALLIANCE	A071102 GBM, adj TMZ +/- Veliparib	A071102	N	
		Y	COG	ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	ARST1321	N	
	GI	Y	ALLIANCE	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	N1048	Y	
	GU	Y	NRG	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG-GU002	N	
	LEUK	Y	SWOG	S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics	S1612	N	
	LUNG	Y	NRG	NRGCC003 SCLC, PCI or HA-PCI	NRG-CC003	Y	
	MELAN	Y	ECOG-ACRIN	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	EA6141	N	
	OTHER	Y	NRG	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG-GY005	Y	
		Y	NRG	R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	RTOG-1216	Y	
		Y	NRG	NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG-HN001	Y	
III	BREAST	N		S1222 Brst,Fulv. +/- Ever. +/- Anastr.		N	Y
		Y	SWOG	S1207 Brst,Adj,Endocrine+/-Everolimus	S1207	Y	
		Y	SWOG	S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	S1418	Y	
		Y	ALLIANCE	A011106 Breast, Neoadj, ALTERNATE study	A011106	N	
		Y	NRG	B51 Breast, Regional Nodal XRT	NSABP-B-51	Y	
		Y	ALLIANCE	A011401 Breast, adj, Stage II/III HER2-, weight loss	A011401	Y	
		Y	NRG	NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG-BR003	N	
		Y	ECOG-ACRIN	E2112 Brst,Adv,Exemestane+/-Entinostat	E2112	Y	
		Y	ALLIANCE	A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	A011502	Y	
		Y	ECOG-ACRIN	EA1151 Brst, Tomosynthesis Mammographic Screening	EA1151	N	
		Y	NRG	B55 Brst, Adj Olaparib for BRCA,TNBC	NSABP-B-55	Y	
	CCD	Y	SWOG	S1415CD TrACER CSF Standing Order Intervention for FN	S1415CD	Y	
		Y	SWOG	S1703 Met Breast, STM-monitoring v Usual Care	S1703	Y	
		Y	ALLIANCE	A011104 Preoperative Breast MRI	A011104	Y	
		Y	ALLIANCE	A191402C PROS, Testing Decision Aids for Minority Men	A191402CD	Y	
	GI	Y	ALLIANCE	A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC	A021502	Y	
		Y	NRG	NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG-GI004	Y	
	GU	Y	SWOG	S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	S1602	Y	
		Y	NRG	R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	RTOG-0924	Y	
		Y	ECOG-ACRIN	EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	EA8143	Y	
		Y	ALLIANCE	A031501 Bladder, MIBC/Loc Adv, Adjuv Pembro vs Obs	A031501	Y	
		Y	ALLIANCE	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	A031102	Y	

## OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

<u>Phase</u>	<u>Comm.</u>	<u>Int</u> <u>grp</u>	<u>Stat</u> <u>Center</u>	<u>Study</u>	<u>NCIPROTO</u>	<u>CA</u> <u>Cntrl</u> <u>Study</u>	<u>Temp</u> <u>Close</u>
LEUK	Y	ECOG-ACRIN	E2906 AML, Age 60+, Clo vs Dauno+Cy	E2906	Y		
	Y	ECOG-ACRIN	E1910 BCR-ABL-neg, B ALL, Blinatumomab	E1910	N		
LUNG	Y	ALLIANCE	C30610 SCLC, Thoracic RT	CALGB-30610	Y		
	Y	ALLIANCE	A081105 ALCHEMIST1, EGFR mut, Erlotinib	A081105	N		
	Y	ECOG-ACRIN	EA5142 ALCHEMIST3, Non-match, Nivolumab	EA5142	N		
	Y	ECOG-ACRIN	E4512 ALCHEMIST2, ALK mut, Crizotinib	E4512	N		
LYMPH	Y	ECOG-ACRIN	EA4151 Lymph, AHCT +/-Ritux, MRD Neg	EA4151	N		
	Y	ALLIANCE	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	A051301	N		
MELAN	Y	ECOG-ACRIN	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	EA6134	Y		
MMYEL	Y	ECOG-ACRIN	E1A11 MM, frontline, BLD vs CLD	E1A11	Y		
OTHER	Y	ALLIANCE	N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	N0577	N		
	Y	NRG	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	GOG-0263	Y		
	Y	NRG	R0724 Cervical, Chem+RT +/- Adj. Chemo	RTOG-0724	Y		
PREV	Y	SWOG	S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	S0820	Y		
	Y	ALLIANCE	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	A211102	Y		
SURV	Y	SWOG	S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	S1501	Y		
	Y	ECOG-ACRIN	E1Q11 EROS: Reproductive Health in Cancer Survivors	E1Q11	Y		
SXQOL	Y	ALLIANCE	A221101 Glioma, Nuvigil/Placebo Fatigue	A221101	Y		
	Y	NRG	NRGGU003 Pros, Post-Prostatectomy HYPOR vs COPORT	NRG-GU003	Y		
	Y	ECOG-ACR	EA8153	EA8153			
	Y	ECOG-ACR	EAQ162CD	EAQ162CD			
	Y	ALLIANCE	A221505	A221505			